This is a Phase 1, open-label, dose-escalation FIH trial to evaluate the safety, reactogenicity and immunogenicity of different dose levels of CVSQIV using an adaptive dose-finding design.
This study aims to evaluate the safety and reactogenicity profile of CVSQIV at different dose levels.